Jan 162023

7 Key Trends for the Global Life Sciences Industry in 2023

GLS Blog Contributor
, , , , , ,

Sidley’s 2023 Global Life Sciences Trendspotting Report maps out seven key trends in the life sciences industry globally, and identifies some regional trends in the U.S., China, and Europe which are likely to have global ramifications during the coming year.

The industry is experiencing increased regulatory and financial pressures in many areas. However, the current economic environment is also generating competitive advantages for the companies most adept at structuring their global product life cycles, supply chains, and business plans across the regions and countries which are still seeking to attract investment.

The key global life sciences trends to watch in 2023:

  1. With a Threatened Recession, Life Sciences Companies and Healthcare Providers Consider Alternative Liquidity Options
  2. Digital Health and Medical Artificial Intelligence Innovation Will Continue at a Breakneck Pace, Requiring a Robust Global Regulatory, Data, and Reimbursement Strategy
  3. Increasingly, Life Sciences and Healthcare Providers Proactively Consider Offensive Challenges to U.S. Government Agencies
  4. Life Sciences and Healthcare Enforcement and Litigation Activity is Increasing
  5. Shifting Regulatory Opportunities and Pitfalls Suggest Biotech Companies Should Pressure-Test Initial Development and Launch Destinations
  6. Environmental, Social, and Governance (ESG) Programs Will Be Subject to Increased Scrutiny
  7. New Privacy and Cyber Laws in U.S., Europe, and China Add Complexity While Enforcement Against Life Sciences Companies Is Rising

This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.

GLS Blog Contributor

sidleyglsblog@sidley.com

You might also like
Risks and Benefits of Generative AI for Pharma Supply Chain Management

As the life sciences sector grapples with complex challenges around sustainability and Environmental and Social Governance (ESG) compliance, Generative AI (GenAI) is emerging as a potentially powerful tool for enhancing efficiency and sustainability. Michele Tagliaferri, Eva von Mühlenen, and Anna-Shari Melin explain.

European Court of Justice Judgment Relating to Orphan Market Exclusivity

In a recent judgment, the Court of Justice of the European Union (CJEU) has shed light on the scope of the ‘clinical superiority’ criteria providing for a derogation to orphan market exclusivity which is key to protect the orphan molecule from competition for the period of market exclusivity (10 or 12 years as the case may be). Marie Manley, Chris Boyle, and Alix Vermulst examine the impact of this judgment on pharmaceutical companies.

European Regulator Clarifies Guidance on the Use of AI in the Medicinal Product Lifecycle

The European Medicines Agency (EMA) has published a final reflection paper on the use of AI in the drug lifecycle, which provides important insights into the expectations from the EMA to clinical trial sponsors, as well as marketing authorization (MA) applicants and holders who use AI systems. Josefine Sommer and Zina Chatzidimitriadou explain.